Drug Development Market Scope and Size by 2031
Drug development is a process, which focuses on identifying a compound therapeutically helpful in treating and curing diseases. Typically, a drug development effort addresses a biological target that has been shown to play a role in developing the disease or starts from a molecule with interesting biological activities. In the recent past, drug development has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time-consuming.
MARKET SCOPE
The "Global Drug Development Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Drug development market with detailed market segmentation by type, technology, end use, and geography. The report provides key statistics on the market status of the leading Drug development market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type, the global Drug development market is segmented into small molecule drugs and biologic drugs.
- On the basis of technology, the market is segmented into high throughput screening, pharmacogenomics, combinatorial chemistry, nanotechnology, and other technologies.
- On the basis of end use, the market is segmented into pharmaceutical companies, contract research organizations (cros), other end users.
MARKET DYNAMICS
Drivers:
- Rise in the incidences of several chronic diseases.
- Increasing R&D expenditure.
- Increasing investment for development of novel drug molecules.
Restraints:
- The stringent regulation and high capital investment are the major restraining factor for this market.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Drug development market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Drug development market in these regions.
IMPACT OF COVID-19ON DRUG DEVELOPMENT MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Drug development market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Drug development market in these regions.
IMPACT OF COVID-19ON DRUG DEVELOPMENT MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the Drug development market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Drug development market are anticipated to lucrative growth opportunities in the future with the rising demand for Drug development in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Drug development market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Genome Biologics
- Abbott Laboratories Inc.
- Agilent Technologies Inc.
- AstraZeneca PLC
- AVIVA Biosciences
- Bayer AG
- Biotica Pharma.
- Bristol-Myers Squibb Company
- Collaborative Drug Development Inc.
- DeepBiome Therapeutics
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Drug Development Market - By Drug Type
1.3.2 Drug Development Market - By Technology
1.3.3 Drug Development Market - By End Use
1.3.4 Drug Development Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DRUG DEVELOPMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. DRUG DEVELOPMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. DRUG DEVELOPMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. DRUG DEVELOPMENT - GLOBAL MARKET OVERVIEW
6.2. DRUG DEVELOPMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. DRUG DEVELOPMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. SMALL MOLECULE DRUGS
7.3.1. Overview
7.3.2. Small Molecule Drugs Market Forecast and Analysis
7.4. BIOLOGIC DRUGS
7.4.1. Overview
7.4.2. Biologic Drugs Market Forecast and Analysis
8. DRUG DEVELOPMENT MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
8.1. OVERVIEW
8.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
8.3. HIGH THROUGHPUT SCREENING
8.3.1. Overview
8.3.2. High Throughput Screening Market Forecast and Analysis
8.4. PHARMACOGENOMICS
8.4.1. Overview
8.4.2. Pharmacogenomics Market Forecast and Analysis
8.5. COMBINATORIAL CHEMISTRY
8.5.1. Overview
8.5.2. Combinatorial Chemistry Market Forecast and Analysis
8.6. NANOTECHNOLOGY
8.6.1. Overview
8.6.2. Nanotechnology Market Forecast and Analysis
8.7. AND OTHER TECHNOLOGIES
8.7.1. Overview
8.7.2. And Other Technologies Market Forecast and Analysis
9. DRUG DEVELOPMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USE
9.1. OVERVIEW
9.2. END USE MARKET FORECASTS AND ANALYSIS
9.3. PHARMACEUTICAL COMPANIES
9.3.1. Overview
9.3.2. Pharmaceutical Companies Market Forecast and Analysis
9.4. CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.4.1. Overview
9.4.2. Contract Research Organizations (CROs) Market Forecast and Analysis
9.5. OTHER END USERS
9.5.1. Overview
9.5.2. Other End Users Market Forecast and Analysis
10. DRUG DEVELOPMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Drug Development Market Overview
10.1.2 North America Drug Development Market Forecasts and Analysis
10.1.3 North America Drug Development Market Forecasts and Analysis - By Drug Type
10.1.4 North America Drug Development Market Forecasts and Analysis - By Technology
10.1.5 North America Drug Development Market Forecasts and Analysis - By End Use
10.1.6 North America Drug Development Market Forecasts and Analysis - By Countries
10.1.6.1 United States Drug Development Market
10.1.6.1.1 United States Drug Development Market by Drug Type
10.1.6.1.2 United States Drug Development Market by Technology
10.1.6.1.3 United States Drug Development Market by End Use
10.1.6.2 Canada Drug Development Market
10.1.6.2.1 Canada Drug Development Market by Drug Type
10.1.6.2.2 Canada Drug Development Market by Technology
10.1.6.2.3 Canada Drug Development Market by End Use
10.1.6.3 Mexico Drug Development Market
10.1.6.3.1 Mexico Drug Development Market by Drug Type
10.1.6.3.2 Mexico Drug Development Market by Technology
10.1.6.3.3 Mexico Drug Development Market by End Use
10.2. EUROPE
10.2.1 Europe Drug Development Market Overview
10.2.2 Europe Drug Development Market Forecasts and Analysis
10.2.3 Europe Drug Development Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Drug Development Market Forecasts and Analysis - By Technology
10.2.5 Europe Drug Development Market Forecasts and Analysis - By End Use
10.2.6 Europe Drug Development Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Drug Development Market
10.2.6.1.1 Germany Drug Development Market by Drug Type
10.2.6.1.2 Germany Drug Development Market by Technology
10.2.6.1.3 Germany Drug Development Market by End Use
10.2.6.2 France Drug Development Market
10.2.6.2.1 France Drug Development Market by Drug Type
10.2.6.2.2 France Drug Development Market by Technology
10.2.6.2.3 France Drug Development Market by End Use
10.2.6.3 Italy Drug Development Market
10.2.6.3.1 Italy Drug Development Market by Drug Type
10.2.6.3.2 Italy Drug Development Market by Technology
10.2.6.3.3 Italy Drug Development Market by End Use
10.2.6.4 Spain Drug Development Market
10.2.6.4.1 Spain Drug Development Market by Drug Type
10.2.6.4.2 Spain Drug Development Market by Technology
10.2.6.4.3 Spain Drug Development Market by End Use
10.2.6.5 United Kingdom Drug Development Market
10.2.6.5.1 United Kingdom Drug Development Market by Drug Type
10.2.6.5.2 United Kingdom Drug Development Market by Technology
10.2.6.5.3 United Kingdom Drug Development Market by End Use
10.2.6.6 Rest of Europe Drug Development Market
10.2.6.6.1 Rest of Europe Drug Development Market by Drug Type
10.2.6.6.2 Rest of Europe Drug Development Market by Technology
10.2.6.6.3 Rest of Europe Drug Development Market by End Use
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Drug Development Market Overview
10.3.2 Asia-Pacific Drug Development Market Forecasts and Analysis
10.3.3 Asia-Pacific Drug Development Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Drug Development Market Forecasts and Analysis - By Technology
10.3.5 Asia-Pacific Drug Development Market Forecasts and Analysis - By End Use
10.3.6 Asia-Pacific Drug Development Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Drug Development Market
10.3.6.1.1 Australia Drug Development Market by Drug Type
10.3.6.1.2 Australia Drug Development Market by Technology
10.3.6.1.3 Australia Drug Development Market by End Use
10.3.6.2 China Drug Development Market
10.3.6.2.1 China Drug Development Market by Drug Type
10.3.6.2.2 China Drug Development Market by Technology
10.3.6.2.3 China Drug Development Market by End Use
10.3.6.3 India Drug Development Market
10.3.6.3.1 India Drug Development Market by Drug Type
10.3.6.3.2 India Drug Development Market by Technology
10.3.6.3.3 India Drug Development Market by End Use
10.3.6.4 Japan Drug Development Market
10.3.6.4.1 Japan Drug Development Market by Drug Type
10.3.6.4.2 Japan Drug Development Market by Technology
10.3.6.4.3 Japan Drug Development Market by End Use
10.3.6.5 South Korea Drug Development Market
10.3.6.5.1 South Korea Drug Development Market by Drug Type
10.3.6.5.2 South Korea Drug Development Market by Technology
10.3.6.5.3 South Korea Drug Development Market by End Use
10.3.6.6 Rest of Asia-Pacific Drug Development Market
10.3.6.6.1 Rest of Asia-Pacific Drug Development Market by Drug Type
10.3.6.6.2 Rest of Asia-Pacific Drug Development Market by Technology
10.3.6.6.3 Rest of Asia-Pacific Drug Development Market by End Use
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Drug Development Market Overview
10.4.2 Middle East and Africa Drug Development Market Forecasts and Analysis
10.4.3 Middle East and Africa Drug Development Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Drug Development Market Forecasts and Analysis - By Technology
10.4.5 Middle East and Africa Drug Development Market Forecasts and Analysis - By End Use
10.4.6 Middle East and Africa Drug Development Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Drug Development Market
10.4.6.1.1 South Africa Drug Development Market by Drug Type
10.4.6.1.2 South Africa Drug Development Market by Technology
10.4.6.1.3 South Africa Drug Development Market by End Use
10.4.6.2 Saudi Arabia Drug Development Market
10.4.6.2.1 Saudi Arabia Drug Development Market by Drug Type
10.4.6.2.2 Saudi Arabia Drug Development Market by Technology
10.4.6.2.3 Saudi Arabia Drug Development Market by End Use
10.4.6.3 U.A.E Drug Development Market
10.4.6.3.1 U.A.E Drug Development Market by Drug Type
10.4.6.3.2 U.A.E Drug Development Market by Technology
10.4.6.3.3 U.A.E Drug Development Market by End Use
10.4.6.4 Rest of Middle East and Africa Drug Development Market
10.4.6.4.1 Rest of Middle East and Africa Drug Development Market by Drug Type
10.4.6.4.2 Rest of Middle East and Africa Drug Development Market by Technology
10.4.6.4.3 Rest of Middle East and Africa Drug Development Market by End Use
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Drug Development Market Overview
10.5.2 South and Central America Drug Development Market Forecasts and Analysis
10.5.3 South and Central America Drug Development Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Drug Development Market Forecasts and Analysis - By Technology
10.5.5 South and Central America Drug Development Market Forecasts and Analysis - By End Use
10.5.6 South and Central America Drug Development Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Drug Development Market
10.5.6.1.1 Brazil Drug Development Market by Drug Type
10.5.6.1.2 Brazil Drug Development Market by Technology
10.5.6.1.3 Brazil Drug Development Market by End Use
10.5.6.2 Argentina Drug Development Market
10.5.6.2.1 Argentina Drug Development Market by Drug Type
10.5.6.2.2 Argentina Drug Development Market by Technology
10.5.6.2.3 Argentina Drug Development Market by End Use
10.5.6.3 Rest of South and Central America Drug Development Market
10.5.6.3.1 Rest of South and Central America Drug Development Market by Drug Type
10.5.6.3.2 Rest of South and Central America Drug Development Market by Technology
10.5.6.3.3 Rest of South and Central America Drug Development Market by End Use
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL DRUG DEVELOPMENT MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. DRUG DEVELOPMENT MARKET, KEY COMPANY PROFILES
13.1. GENOME BIOLOGICS
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ABBOTT LABORATORIES INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. AGILENT TECHNOLOGIES INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. ASTRAZENECA PLC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. AVIVA BIOSCIENCES
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. BAYER AG
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. BIOTICA PHARMA
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BRISTOL-MYERS SQUIBB COMPANY
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. COLLABORATIVE DRUG DISCOVERY INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. DEEPBIOME THERAPEUTICS
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Genome Biologics
2. Abbott Laboratories Inc.
3. Agilent Technologies Inc.
4. AstraZeneca PLC
5. AVIVA Biosciences
6. Bayer AG
7. Biotica Pharma.
8. Bristol-Myers Squibb Company
9. Collaborative Drug Discovery Inc.
10. DeepBiome Therapeutics
11. Eli Lilly and Company
12. F. Hoffmann-La Roche Ltd
13. Gilead Sciences Inc.
14. GlaxoSmithKline PLC
15. Merck & Co. Inc.
16. Novartis
17. Pfizer Inc.
18. Shimadzu Corp.
19. Takeda Pharmaceuticals
20. Teva Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For